AAMU
CLDX icon

Amundi Asset Management US’s Celldex Therapeutics CLDX Stock Holding History

Amundi Asset Management US’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-3,733
Closed -$28K – 1613
2018
Q2 		$28K Buy
3,733
+533
+17% +$7.13K ﹤0.01% 1528
2018
Q1 		$112K Buy
+3,200
New +$124K ﹤0.01% 1396

Other funds holding CLDX

KE
KLP Enterprises Branford, Connecticut $1.97M AUM
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
TCMG
TSP Capital Management Group Summit, New Jersey $410M AUM 71.81% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Amundi Asset Management US's CLDX Position: Q3 2018 in Review

Amundi Asset Management US sold out of Celldex Therapeutics (CLDX) in Q3 2018, closing a stake of 3,733 shares — an estimated $28K sold.

Amundi Asset Management US first reported a position in CLDX in Q1 2018 and held it in 2 quarters. The position peaked at $112K in Q1 2018. 95 funds tracked by Wall St. Rank hold CLDX as of Q3 2018.

  • Amundi Asset Management US reported no remaining Celldex Therapeutics position as of Q3 2018 after selling out during the quarter.
  • Amundi Asset Management US sold 3,733 Celldex Therapeutics shares in Q3 2018, an estimated $28K.
  • Amundi Asset Management US first reported a position in Celldex Therapeutics in Q1 2018 and held it in 2 quarters.
  • Amundi Asset Management US's Celldex Therapeutics position peaked at $112K in Q1 2018.
  • 95 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q3 2018.

Based on Amundi Asset Management US's 13F filing for Q3 2018, filed 14 Nov 2018.